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Abstract
Subclinical Hypothyroidism, SCH, has been detected with increasing frequency in recent years and has brought about major
controversies regarding management and treatment [Meier et al., 2001].The condition is characterized as having a high concentration of thyroid stimulating hormone, yet normal thyroid hormone levels and is often asymptomatic. Scientific articles retrieved
from various databases helped determine some of the long term risk factors associated with SCH, including progression to overt
hypothyroidism, fatty liver disease, cardiovascular disease, neuropsychiatric complications and reproductive malfunctions. Studies
determining the clinical and metabolic effects of L-thyroxine hormone replacement therapy on symptoms and potential risks of
SCH on various patient populations were investigated and compared to controls that were not treated or were given a placebo
drug. After considering both the arguments promoting treatment and others opposing it, conclusions were drawn regarding the
promotion or discouragement of hormonal treatment for patients in different age brackets and stages of life. In general, the
greatest benefits of treatment are observed in patients with thyroid-stimulating hormone levels ranging over 10mIU/L, younger
patients with slightly elevated thyroid-stimulating hormones who are at risk for cardiovascular disease and for pregnant women
with gestational SCH. On the contrary, L-thyroxine treatment therapy is not as crucial for the elderly population or patients with
slightly elevated thyroid-stimulating hormone values when there are no apparent symptoms of hypothyroidism being experienced.
Introduction
Describing a condition as ‘subclinical’ implies that it is asymptomatic, thereby suggesting that a less aggressive treatment plan is
needed and possibly rendering the condition unworthy of treatment altogether. However, there is controversy regarding whether the condition is indeed ‘subclinical’ and if it is necessary or
beneficial to treat. Hypothyroidism is an endocrinological disorder in which there is inadequate production of thyroid hormones,
triiodothyronine (T3) and thyroxine (T4) by the thyroid gland.
These hormones strongly influence energy metabolism, digestion
and body heat production. Additionally, they play a key role in cardiac contraction rate, memory, psychological health and sleep. In
the case where the gland itself fails to secrete sufficient hormone
concentrations, the disease is considered primary. However, if the
root of the problem is traced back to insufficient stimulation of
a structurally healthy gland due to decreased thyroid-stimulating
hormone (TSH) released from the adenohypophysis, then the
condition is regarded as secondary or central. Diminished secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus would cause the condition to be considered tertiary hypothyroidism [Hadley & Levine, 2007; Wiersinga, 2010]. Subclinical
hypothyroidism (SCH) ranks as a grade of primary hypothyroidism and is characterized biochemically as an elevated serum TSH
concentration, with a normal serum-free T4 level, as well as T3
level [Meier et al.,2001].When a patient’s thyroid function is normal and hormone secretion is balanced according to homeostasis,
he/she is considered euthyroid. Euthyroid adults should exhibit
TSH levels within a range of 0.2-7.6 mIU/L, a T3 concentration
of 4.3-12.5 mcg/dL and a free T4 concentration of 0.7-1.7 ng/dL
[Robertson, Shilkofsky 2005]. Some experts have suggested that
the TSH upper limit should be only 2.5 or 3 mU/L, while others
argue that the serum TSH distribution gradually shifts towards
higher values with age and must be adjusted accordingly. Others
have proven through their studies that the accepted reference
range for serum TSH should be altered as patients age and that
maintaining a 4.5 mIU/L upper limit for TSH concentration results
in the prevalence of SCH to be significantly overestimated in the
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elderly population. Nonetheless, while there is controversy over
the appropriate upper limit of normal serum TSH, most laboratories agree that it is 4 to 5 mIU/L [Surks et al.,2007]. Biochemical
testing and laboratory test results alone are required in order
to diagnose SCH since patients often present with vague symptoms elevated TSH levels. Much research has been done regarding whether to treat SCH in populations of various age brackets
and stages. A general consensus has been reached based on the
existing and potential risk factors involved and the success rates
of levothyroxine thyroid hormone replacement.

Methods
Relevant information was accumulated via original research
literature obtained from databases such as Google Scholar,
Proquest , Pubmed and Touro College’s Online Library . Medical
journals, JCEM and JAMA, served as a source of information
as well. Books, including a medical book and science textbook,
were used to provide background information. All content was
critically analyzed and compared to assure validity.

Epidemiology
Based on the results of population-based studies, the prevalence of SCH in adults ranges from 4 to 15 percent [Turnbridge
et.al., 1977] and affects approximately 10 million people in the
Unites States [Huber et al., 2002]. In one of the best longitudinal
studies conducted, Turnbridge et al. (1977) found that 7.5% of
women and 2.8% of men of all ages in Whickham, England have
TSH levels exceeding 6 mlU/L. Twelve such studies done within different cultures, similar to theirs, were reviewed, and they
concluded that primary thyroid-gland malfunction occurs in
approximately 5% of any population. Of the 16,533 participants
in the Unites States Third National Health and Examination
Survey (NHANES III), 4.3% had SCH [Hollowell et.al., 2002].
Of the 25,862 participants included in the Colorado Thyroid
Disease Prevalence Study, an elevated TSH level was found in
9.5% of the population [Canaris et. al., 2000]. Furthermore, the
frequency of SCH is found to be higher in females than males,
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rises with age and is less in blacks than in whites [Kanaya et
al., 2002]. It is important to note that since thyroid hormones
contain iodine, the inhabitants’ thyroid functioning is highly dependent on the iodine reserve of their specific region. When
analyzing population-based studies, it’s crucial to consider how
the degree of iodine repletion or depletion in that geographical
environment affects its populations intake and in turn, thyroidal health [Laurberg et al., 1998]. For example, in Africa, lack
of dietary iodine is the chief determinant of thyroid pathology,
instigating a spectrum of iodine deficiency disorders, including
hypothyroidism [Okosieme, 2006].

Clinical Findings
While the clinical manifestations of SCH vary, patients sometimes report mild signs and symptoms similar to those experienced due to overt hypothyroidism. However, these symptoms
are characterized as neither sensitive nor specific [Meier et
al., 2001]. Based on the Colorado Thyroid Disease Prevalence
Study involving 2,336 participants with SCH, symptoms reported by patients with SCH included dry skin (28%), poor memory (24%), slow thinking (22%), muscle weakness (22%), fatigue
(18%), muscle cramps (17%), cold intolerance (15%), puffy eyes
(12%), constipations (8%) and a hoarser voice(7%) [Canaris
et al., 2000]. Conflicting data is seen from a community-based
cross-sectional study where 1,423 participants, ranging from
ages 18-75 years old, had TSH screenings and their symptoms
were evaluated.The data collected indicated that subclinical thyroid disease is not associated with lower well-being or impaired
health-related quality of life. Therefore, attempts to clinically
identify SCH based on reported symptoms are unsuccessful
[Bell et al., 2007]. However, significant evidence highlights numerous long-term consequences of SCH, though they do not
appear obvious from patients’ reports.

Progression to Overt Hypothyroidism
A significant number of patients with SCH eventually develop
overt hypothyroidism. In a study done by Huber et al., after a
mean observation period of 9.2 years, 23 out oof 82patients
(28%) who entered the study with subclinical hypothyroidism
developed overt hypothyroidism, as defined by low T4 concentration and elevated TSH (>20 mU/L).The risk of progression to
overt hypothyroidism was seen to correlate to the initial serum
TSH level of the patient; the higher the concentration, the greater the risk. Of the 82 women with TSH concentration values
ranging from 4-6 mIU/L, the frequency of progression to overt
hypothyroidism was 0% after 9.2 years. When only the patients
with a serum TSH concentration above 6 mIU/L were evaluated (n = 61), after 10 years, the cumulative incidence of overt
hypothyroidism was 55.3% [Huber et al., 2002]. Overt hypothyroidism is particularly common in older patients whose TSH
levels exceed 10 mIU/L or those who have circulating thyroid

antibodies [Ayala et al., 2000]. Obviously, overt hypothyroidism
poses a greater threat to one’s overall health related quality of
life as it presents with classical symptoms of fatigue, depression,
weight gain, cold intolerance, bradycardia, constipation, dry skin,
facial edema and loss of hair [Carle et al., 2014]. More severe
dysfunction of the thyroid gland also stimulates a negative feedback mechanism in which more and more TSH is secreted, ultimately causing the gland to swell, referred to as goiter.

Fatty-liver Disease
Since thyroid hormones play a fundamental role in lipid metabolism, mild hypothyroidism may cause hypercholesterolemia
and play an essential role in the pathogenesis of non-alcoholic
fatty liver disease (NAFLD). Non-alcoholic fatty liver disease is
defined as “extrahepatic accumulation of fat in the absence of
excess alcohol consumption” [Liu et al., 2017]. A cross-sectional
study reported the prevalence of fatty-liver disease and abnormal liver enzyme levels to increase progressively with rising TSH
levels compared to patients with euthyroidism, suggesting associations between the spectrum of SCH and liver malfunction. In
one study population, the incidence of fatty-liver disease and abnormal liver enzyme level was 29.9% and 20.1%, respectively, for
patients with SCH [Chung et al., 2012]. SCH patients experience higher amounts of liver aspartate aminotransferase (AST)
and alanine aminotransferase (ALT), an enzyme released into
the bloodstream when the liver is damaged [Liu et al., 2017].

Cardiovascular Disease
Thyroid hormones are known to affect the heart and vasculature. As a result, the impact of SCH on the cardiovascular
system has become an important subject of research [Liu et
al., 2010]. While it is undisputed that overt hypothyroidism is
linked to increased risk for cardiovascular diseases (CVD), conflicting data raises controversy whether SCH is also associated
with heart disease. Heterogeneity among individual studies can
be explained by the different TSH cutoffs used, varying cardiovascular disease definitions or differences in participants’ age,
gender, or severity of SCH (as measured by TSH level) [Rodondi
et al., 2010]. Clinical hypothyroidism has been known to cause
an increase in blood pressure. Since thyroid hormone directly
acts on arterial smooth muscle cells of blood vessels, causing
vasodilation, when hypothyroidism occurs, a lower hormone
level increases the vascular resistance and in turn the level of
blood pressure. In a cross-sectional survey the incidence of high
blood pressure, hypertension, in the SCH group was significantly higher than the control, the euthyroid group. The conclusions
drawn from this study coincide with previous data collected by
Luboschitzky et al. in 2002 [cited in Liu et al., 2010].
Furthermore, since SCH has been linked with abnormal lipid
metabolism, it is consequently related to increased risk for
coronary heart disease. An increased serum total cholesterol

73

Rachel Kaufman

and low density lipoprotein cholesterol (LDL-C) was detected
as a feature of SCH in some of the literature, while contrasting research found cholesterol levels to be in normal range.
Nonetheless, several studies suggested a connection between
SCH and development of atherosclerosis, and more recently
published research established SCH as a risk factor for myocardial infarction [Meier et al., 2001; Anderson et al. 2015]. A
meta-analysis from 7 studies, including 2,020 patients with SCH,
confirmed a substantial trend of increased risk of coronary
heart disease by highlighting events like nonfatal myocardial
infarction, angina and necessary coronary revascularizations
common to patients with elevated serum TSH concentrations,
especially of those that were 10 mIU/L or greater. Results from
a meta-analysis of patient-level data from 11 prospective cohort
studies showed greater risk for coronary heart disease mortality for patients suffering from SCH with serum TSH concentrations above 10mIU/L. Rodoni et al. reported increased systemic
vascular resistance, arterial stiffness, altered endothelial function, increased atherosclerosis and altered coagulability to be
associated with SCH and the acceleration of development of
coronary heart disorder. On the contrary, minimal TSH elevation (4.5-6.9 mIU/L) was not linked to cardiovascular disease or
mortality [Rodoni et al., 2010].

Neuropsychiatric Symptoms
While there is evidence that SCH is linked to neuropsychiatric
complications, there has been conflicting research as well. One
study assessed the history of major depression in subjects with
SCH compared to euthyroid subjects. The frequency of depression was substantially higher in those who met the criteria for
SCH (56%) than in those who did not (20%), suggesting that
SCH may lower the threshold for the occurrence of depression
[Haggerty et al., 1993]. Similar results were found in a later study
where signs of neuropsychiatric dysfunction like somatization,
cognitive impairment disturbances, psychomotor retardation
and sleep disorders were seen in 63.5% of a population with
mild thyroid failure [Demartini et al., 2010]. However, another
study revealed opposite research as patients with SCH scored
equally as well as the euthyroid control group on 14 cognitive
function tests [Jorder et al., 2006].

Reproductive Malfunctions
Alteration of the thyroid’s physiology under the impact of placental human chorionic gonadotropin (hCG) during the first
trimester, results in adjustments to TSH levels. During the first
trimester, a white woman maintains an upper limit TSH concentration of 2.5 mIU/L and 3.0 mlU/L during her second and third
trimester periods [Stagnaro-Green et al., 2011]. SCH during
gestation poses fewer risks than overt hypothyroidism would,
but still puts women at increased risk for preterm delivery at or
before 34 weeks of gestation, placental abruption (3 times more
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likely to occur in women with SCH) and/or pregnancy loss
compared to euthyroid women. Severe preeclampsia, defined as
gestational hypertension is noted as a risk factor for pregnant
women with SCH [Casey et al. 2005;Novakovic et al., 2018].
A meta-analysis of 15 cohort studies involving 1,896 pregnant
women with SCH arrived at conclusions similar to Novakovik
et al. and showed that SCH during gestation causes significant
impairment to the intelligence and neurological development of
the offspring [Liu et al., 2018].
It’s possible to acquire SCH as a result of pregnancy; an estimated 15% of pregnancies in the U.S are affected by gestational
SCH [Blatt et.al., 2012]. Over the gestational period, increased
metabolic needs result in increased production of thyroid hormones by approximately 50% compared to euthyroid, non-pregnant women. Consequently, necessary daily iodine intake levels
rise by 50%. More renal blood flow and glomerular filtration
results in an increase in iodide clearance from blood plasma.
Thus, more iodine is necessary in the diet of a pregnant woman.
The stress imposed on the thyroid gland during gestation results in SCH for many women with compromised dietary iodine levels. Clinical studies have proven that iodine deficiency
during gestation causes impaired development of the brain and
impedes mental function development of the fetus [Farebrother
et al., 2015 ]. Measuring the IQ of children whose mothers had
not been treated for SCH during pregnancy revealed mean IQ
scores of 7 points lower than controls [Haddow et al., 1999].
Casey et al. (2005) proposed that preterm parturition results in
prematurity which contributes to neurodevelopment delay and
reduces intelligence quotient.

Effects of Levothyroxine Hormone Replacement
In general, the research showing correlation between T4 replacement and improvement of hypothyroid symptoms is conflicting and is probably due to differences in the populations
studied, various TSH cut-off concentrations and age range.
Levothyroxine, which is a synthetic form of T4, is usually administered to patients suffering from overt hypothyroidism.
Nevertheless, there is much controversy whether patients exhibiting mild thyroid failure with similar symptoms should be
prescribed levothyroxine as well [Meier et al., 2001]. Some, but
not all, research conducted show how treatment facilitates improvement of hypothyroid symptoms experienced by patients
with SCH. Subjects with mild thyroid failure who were treated with L-thyroxine showed significantly greater improvement
in overall hypothyroid symptoms than did subjects who were
given placebo [Cooper et al., 1984]. Nonetheless, in all the clinical trials reviewed, with ongoing dosage monitoring, L-thyroxine
succeeded in lowering previously elevated TSH concentrations
to healthy levels.
By decreasing TSH concentration to euthyroid levels,
L-Thyroxine prevents the progression to overt hypothyroidism
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[Ayala et al., 2000]. Following T4 treatment, ultrasound verified
80% thyroid volume reduction in patients with goiter [Romaldini
et al., 1996]. In one study, L- thyroxine and a placebo drug were
randomly administered to 63 female patients over a span of 48
weeks in order to achieve euthyroid TSH levels. In the thyroxine treated group, the mean serum TSH concentration was 12.8
± 1.4 mIU/liter before and 3.1 ± 0.3 mIU/liter after treatment,
whereas TSH levels remained unchanged in the control group.
When lipid concentrations were measured after thyroxine
treatment, it was observed that the total cholesterol and low
density lipoprotein cholesterol decreased substantially, especially in those with TSH concentrations of 12 mIU/L and above.
From the observed improvement, it is approximated that treatment reduces the risk of cardiovascular disease and mortality by
9-31%. In contrast, no change in any variable of thyroid function
occurred in the placebo group (Meier et al., 2001). Substantial
improvement of cardiac function in treated patients was reflected by a sensitive measure of myocardial contractility [Cooper
et al., 1984]. In a study done in Copenhagen, Denmark, the participating cohort included patients over 18 years old with the
mean age being 55.2 years. The total of 12,212 subjects were
subdivided into 2 groups, one with TSH levels of 5-10 mIU/L and
another with TSH levels above 10 mIU/L; some were treated
from both groups. In this large cohort study no association between treatment and risk of myocardial infarction or mortality
was revealed, besides in younger patients where it may seem
that treatment had marginal protective advantage. However,
limitations of the study such as no access to patients’ blood
pressure or serum lipid levels and a relatively short follow-up
period of 5 years cause it to have less credence since patients
could have suffered from cardiac complication later on in time
[Anderesen et al., 2015].
A study involving 415 patients with SCH (defined as TSH ≥
4.2 mlU/L) administered levothyroxine to measure its effect on
non-alcoholic fatty liver disease and abnormal liver enzyme levels. After treatment with LT4, the incidence of fatty liver disease
in patients with more pronounced SCH (TSH concentration
≥10 mlU/L) reduced from 48.5% to 24.2%, while in patients
with milder SCH (TSH concentration 4.2-10 mlU/L), frequency of fatty liver disease and alanine aminotransferase was not
significantly altered by LT4 supplementation. However, mild
SCH patients with elevation of total cholesterol who received
LT4 treatment showed decreases in the incidence of fatty liver
disease and serum alanine aminotransferase levels. Those with
higher TSH values experienced a decrease of 5.61 IU/L in serum
aspartate aminotransferase and a small decrease in serum alanine aminotransferase. Patients with milder SCH showed a
reduction in serum alanine aminotransferase from 19.09 IU/L
to 17.95 IU/L, yet serum aspartate aminotransferase remained
stable throughout the study in the untreated, mild SCH control

group. Observing how these parameters became less prevalent
in patients who received treatment, but remained comparably
stable in patients who weren’t treated, provides concrete evidence of the success LT4 therapy has with prevention of non-alcoholic fatty liver disease [Liu et al., 2017].
In another randomized double-blind, placebo-controlled trial,
TSH values decreased by 8.6 mIU/L. Patients treated with with
LT4 showed improved psychometric memory score involving
their thinking, memory and attention versus untreated control
patients [Jaeschke et al., 1996]. Unfortunately, in another study,
LT4 treatment was not enough to generate complete remission of
depressive symptoms, suggesting psychiatric evaluation in patients
affected in this way by SCH is needed [Demartini et al., 2010].
Regarding SCH during gestation, miscarriage was significantly
less frequent among treated women compared to untreated
women in a national U.S. cohort of 5,405 pregnant women.
However, the treated group also had increased odds for
preterm delivery, gestational diabetes and preeclampsia [Maraka
et al., 2017]. Conflicting data claims LT4 decreased the rate of
preterm delivery considerably in pregnant women who received treatment compared to their control who did not (SCH
defined as TSH ≥4 MIU/L; 5.3% incidence for treated women
versus 29.4% in control group) [Nazarpour et al., 2017]. Further
complicating the matter, another study revealed no difference
in the prevalence of preterm delivery, gestational hypertension,
miscarriage rates or adverse fetal outcomes between women
who received LT4 treatment and those who got the placebo
[Casey et al., 2017]. During pregnancy, beginning treatment for
compensated maternal iodine status to ensure proper brain
development in the fetus is extremely time-sensitive; until the
end of the second trimester, iodine treatment protects the
neurological system from consequences of iodine deficiency.
Since head circumference reflects brain mass, the head circumference of an underdeveloped child will be significantly diminished. Microcephaly, where head circumference is more than 3
standard deviations below the norm, was diagnosed in 27% of
children of untreated mothers as opposed to 11% frequency in
their treated control [Cao et al., 1994]. Yet, opposing data says
that no significant discrepancies are noted when comparing IQ
scores and neurodevelopment of 5 year old children of mothers
who received LT4 to those who took the placebo drug [Casey
et al., 2017]. Additional research trials are needed to determine
whether LT4 therapy during gestation prevents adverse outcomes, possibly induces some issues or simply doesn’t have any
effect at all.
In opposition to treating SCH, various studies, such as the
meta-analysis of 12 clinical trials (9 of them with TSH concentration cut-offs of less than 10,12 and 15 mU/L), show no changes in hypothyroid symptoms or quality of life in the treated
group versus the control, the group who received the placebo
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drug [Villar et al., 2007]. While SCH and cognitive dysfunction
have been linked, T4 treatment in a population over 65 years
of age proved it to be ineffective for aiding cognitive function
[Parle et al., 2010]. Similarly, a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults (65 years
of age+, TSH levels ranging from 4.60-19.99 mIU/L with a mean
TSH of 6.40±2.01 mIU/L) concluded that there are no apparent
benefits to L-thyroxine treatment in the quality of life in older
adults. There was no benefit observed in regard to hypothyroid
symptoms, executive cognitive function as measured by the
letter-digit coding test or degree of lethargy experienced by
the group whom received treatment. However, after 12 months,
the mean TSH level was 5.48±2.48 mIU/L in the placebo group,
as compared with 3.63±2.11 mIU/L in the levothyroxine group;
clearly, in terms of reaching healthy TSH levels, the treatment
was successful [Stott et al., 2017].
While research supports that untreated SCH during pregnancy is linked to many adverse obstetric outcomes, many
claim that insufficient evidence exists supporting the benefit
of LT4 therapy on clinical improvement for women with SCH.
Implementing guidelines to treat all pregnant women with SCH
would lead to prescription of LT4 for up to 600,000 pregnant
women in the U.S every year which would obviously have enormous impact on the cost of healthcare [Maraka et al., 2017]
Strengthening the argument that SCH should not be treated,
there is potential danger for a patient to overdose on levothyroxine, causing TSH values to decrease abnormally. Statistical
analysis claims that the incidence of this is as frequent as 1033% as treated SCH patients exhibit unusually low TSH levels.
Overtreatment would completely reverse the original condition
inducing symptoms of excess thyroid hormone. Many times,
this is due to polypharmacy and drug interaction; research
done reiterates the importance in monitoring TSH therapy in
the older population, because of risk of over-replacement. In
their trial with 339 thyroid hormone users, 41% had a low TSH,
16% had a high TSH, and 43% were in the euthyroid range after
treatment [Parle et al., 1993;Somwaru et al., 2009]. Additionally,
those against treatment resent the lifelong commitment to daily
medication in asymptomatic patients, and the cost for both the
hormone and for consistent monitoring of its efficacy.

poses no doubt to experts and healthcare providers in their
unanimous decision to err on the side of caution and prescribe
levothyroxine substitution for both the mother’s and fetus’s advantage. Adverse obstetric effects and risk factors far outweigh
any arguments against treatment. However, treatment of patients
with minimally elevated TSH values (between 4.5 and 10 mlU/L;
differing depending on individual study TSH cut-off) demonstrated minimal change in health related quality of life and only
burdened patients with responsibilities to monitor treatment
and cover its cost, suggesting that these patients not be treated.
However, based on the increased protection against cardiovascular disease and mortality in treated younger patients (<65
years) with TSH ranging from 7 to 9.9 mIU/L, some recommend
treatment. But in the elderly population where LT4 treatment
exacerbates the issue of polypharmacy and may instigate harmful drug-interactions, coupled with the fact that there is a lack of
treatment trials showing benefit of treatment in this population,
only those who present with symptoms suggestive of hypothyroidism should be treated. Of course, long-term monitoring and
annual clinical evaluation of TSH concentration should be implemented to help ensure optimal dosage. Whether reference
ranges should be adjusted for age, implementing a higher cutoff
for starting treatment in older patients, awaits further research.
Future research clarifying the reference ranges for thyroid function tests, specifically the upper limit for TSH, will help resolve
conflicting data and enable researchers to easily compare data
from different clinical trials in order to determine whether or
not the condition requires levothyroxine treatment.

Conclusion

Blatt, A.J., Nakamoto, J.M., Kaufman, H.W. (2012). National
status of testing for hypothyroidism during pregnancy and
postpartum. The journal of clinical endocrinology and metabolism, 97(3), 777-84. https://doi.org/10.1210/jc.2011-2038

Based on the results of T4 replacement successfully reducing
hypothyroid symptoms and potential risks associated with SCH
in certain populations, it is recommended that LT4 replacement
be given to those patients who present with abnormal thyroid
function tests. The most obvious benefit appears to be limited
to patients with baseline TSH levels of ≥10 mIU/L as they are
most likely to experience progression to overt hypothyroidism,
atherosclerosis, myocardial infarction and non-alcoholic fatty
liver disease.The research regarding pregnant women with SCH
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